News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Brand Insights - Thought Leadership | Paid Program | Lash Group

Evaluating Electronic Benefit Verification Solutions for Your Patient Support Program

ByMyra Reinhardt, Brand Insights Contributor, VP of Product Innovation and Analytics, Lash Group
December 31st 2019

Brand Insights - Thought Leadership from Marketers I Paid Program

As specialty therapies evolve and more treatment options for chronic and complex diseases become available, patients are seeking treatment options that are both effective and affordable.

Advertisement
Advertisement

Trending on PharmExec

1

Pfizer Receives Unsolicited Mini-Tender Offer for 1 Million Shares from Tutanota: Report

2

Pharmaceutical Executive Daily: Pfizer Warns Shareholders to Reject Mini-Tender Offer

3

How Do Recent Actions from FDA Provide Insight to the Agency's Enforcement Posture?

4

Gilead Sciences Enters $2.1 Billion Definitive Agreement to Acquire Ouro Medicines

5

Why CMS Is Tightening ASP Reporting and What Manufacturers Must Get Right

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us